Alkermes plc (ALKS) on Wednesday announced positive topline results from its Vibrance-2 Phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Shares rose more than 7% in pre-market trading.
NT2 is a rare, chronic neurological sleep disorder that affects the brain's ability to regulate the sleep-wake cycle.
In Vibrance-2, alixorexton met both primary endpoints, showing statistically significant and clinically meaningful improvements from baseline versus placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight. The drug was generally well tolerated at all doses tested.
Alkermes plans to initiate a Phase 3 study of alixorexton in narcolepsy in the first quarter of 2026.
A Phase 2 trial, dubbed Vibrance-3, evaluating alixorexton in idiopathic hypersomnia (IH), is currently ongoing.
Alkermes stock closed at $33.81, up 3.55% on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.